Morgan Stanley Upgrades Relypsa, Inc. (RLYP) to Equalweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Cantor Fitzgerald Downgrades Relypsa, Inc. (RLYP) to Hold
July 26, 2016 7:38 AM EDTCantor Fitzgerald downgraded Relypsa, Inc. (NASDAQ: RLYP) from Buy to Hold with a price target of $32.00 (from $41.00).
For an analyst ratings summary and ratings history on Relypsa, Inc. click here. For more ratings news on Relypsa, Inc. click here.
Shares of Relypsa, Inc. closed at $31.97 yesterday.
... MoreGalenica to Acquire Relypsa (RLYP) for $32/Share
July 21, 2016 5:42 AM EDTGalenica Group and Relypsa, Inc. (Nasdaq: RLYP) announced that the companies have entered into a definitive agreement under which Galenica will acquire Relypsa. This transaction further strengthens Galenicas Business unit, Vifor Pharma, as the company will gain full global rights to the potassium binder Veltassa (patiromer) for oral suspension and enhance its growing position as a global specialty pharmaceutical company. Under the terms of the merger agreement, Galenica will pay $32 per share in cash, or a total of approximately $1.53 billion. Through this acquisition, Vifor Pharma will gain a fully-integrated commercial organization in the United... More
